Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JYP0066
- Development stage
- Phase 2
- Lead developer
- Guangzhou Jiayue Pharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
JYP0066 is a potent and selective small molecule inhibitor of Janus kinase 1 (JAK1) being developed by Guangzhou Jiayue Pharmaceutical Technology Co., Ltd. Designed for topical application, it is primarily indicated for the treatment of atopic dermatitis. The drug works by interrupting the JAK-STAT signaling pathway, which is responsible for the transduction of signals from several key pro-inflammatory cytokines, including IL-4, IL-13, and IL-31, which drive the inflammation and pruritus associated with atopic dermatitis. By targeting JAK1 specifically, JYP0066 aims to provide therapeutic efficacy while potentially minimizing the systemic side effects associated with non-selective JAK inhibition. It is currently undergoing Phase II clinical trials in China.
02
Targets
Beyond the preview
Go deeper on JYP0066.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JYP0066.